![Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer](https://www.spandidos-publications.com/article_images/mco/14/6/mco-14-06-02291-g01.jpg)
Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer
![Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version - NCI Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version - NCI](https://nci-media.cancer.gov/pdq/media/images/618025.jpg)
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version - NCI
![Overall survival of patients with stage III ovarian cancer according to... | Download Scientific Diagram Overall survival of patients with stage III ovarian cancer according to... | Download Scientific Diagram](https://www.researchgate.net/publication/258118018/figure/fig3/AS:203216982679560@1425462112193/Overall-survival-of-patients-with-stage-III-ovarian-cancer-according-to-reassigned.png)
Overall survival of patients with stage III ovarian cancer according to... | Download Scientific Diagram
![PDF) Should we modify the current FIGO staging system for stage IIIC ovarian cancer? | Hee-Sug Ryu - Academia.edu PDF) Should we modify the current FIGO staging system for stage IIIC ovarian cancer? | Hee-Sug Ryu - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/74335135/mini_magick20211107-6542-9azoez.png?1636323912)
PDF) Should we modify the current FIGO staging system for stage IIIC ovarian cancer? | Hee-Sug Ryu - Academia.edu
![IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer](https://www.mdpi.com/ijerph/ijerph-17-02213/article_deploy/html/images/ijerph-17-02213-g001-550.jpg)
IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
![Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival | Journal of Translational Medicine | Full Text Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival | Journal of Translational Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12967-020-02295-y/MediaObjects/12967_2020_2295_Fig1_HTML.png)
Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival | Journal of Translational Medicine | Full Text
![Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study](https://www.ejso.com/cms/asset/f3e2f230-b13a-4aa6-91a7-9dc89ae7bf61/gr2.jpg)
Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study
![Primary Debulking Surgery for Stage III Epithelial Ovarian Cancer Has a Better Outcome Than Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery Primary Debulking Surgery for Stage III Epithelial Ovarian Cancer Has a Better Outcome Than Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery](https://html.scirp.org/file/3-8903008x2.png)
Primary Debulking Surgery for Stage III Epithelial Ovarian Cancer Has a Better Outcome Than Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery
![Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial - The Lancet Oncology Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/4e3db29c-6a21-4c91-bf2d-cb0508014e18/gr1.gif)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial - The Lancet Oncology
![Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution | In Vivo Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution | In Vivo](https://iv.iiarjournals.org/content/invivo/33/5/1521/F3.large.jpg)